Express Scripts said this week that it expects US drug spending to rise about 2% over the next 3 years, lower than projected inflation rates. However, a lack of competition will affect 2 of the costliest categories of pharmaceuticals—inflammatory conditions and diabetes—between 2019 and 2021.
Express Scripts said this week it expects US drug spending to rise about 2% over the next 3 years, lower than projected inflation rates.
However, a lack of competition will affect 2 of the costliest categories of pharmaceuticals—inflammatory conditions and diabetes—between 2019 and 2021, Express Scripts said in its annual drug trend report. Biosimilar savings for rheumatoid arthritis and other inflammatory conditions will not begin to show up in earnest until 2020, the company said, so cost increases for brand-name drugs will continue.
In diabetes, competition for sitagliptin (Januvia) generics will not become available until 2023. The aging population as well as the increase in obesity will continue to drive usage of diabetes medications, the report said.
In another category, multiple sclerosis, pharmaceutical spending declined in 2018 but may reverse in the next 3 years, Express Scripts said, due to a market shift as patients switched from an older medication, dimethyl fumarate, to a biologic: ocerelizumab.
The pharmacy benefits manager (PBM), which recently merged with Cigna, also touted the fact that its commercial clients saw a spending increase of just 0.4%, which the company said was a 25-year low. Half of the plans decreased drug spending in 2018, up from 44% the year before.
Spending on specialty drugs rose 9.4%, mostly due to better access to therapies, the company said. Spending on traditional, non-specialty medications fell 5.8%.
The company cited its value-based care program for helping to achieve lower increases, and said plans enrolled in the program performed better than traditional plans. As one example, it said plans using its diabetes care management program spent 4.3% less in 2018 even as utilization went up; plans not enrolled spent 7.5% more.
Despite list price inflation of 7.3% for the most commonly used traditional brand medications in 2018, drug costs for traditional drugs fell by 6.5% for employer-sponsored plans, 5.5% for Medicare plans, and 5.6% for exchange plans.
Inflammatory drugs comprised the costliest therapy class for the third year in a row, costing employers $174.45 per member per year, up 14%. Diabetes came in second at $114.85 per member per year, an increase of 4.1%. Spending on insulin, which accounts for 15.3% of diabetes prescriptions, increased just 0.3% in 2018, with a 1.5% decline in unit costs and a 1.8% rise in utilization. In 2018, patients paid 16.9% of total insulin costs, an average of $43.19 per prescription, up $3.33 from 2017.
The Express Scripts report was released the day after President Trump’s State of the Union address, in which he promised once again to lower drug prices, and the same week that HHS Secretary Alex Azar made the rounds at various health policy conferences vowing to bring an end to rebates in an effort to create a more transparent pricing system. Last week, HHS released a rule that, if enacted, would block rebates and discounts given to PBMs, Part D plans, and Medicaid managed care organizations
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.